Form 8-K

8-K — TherapeuticsMD, Inc.

Accession: 0001213900-26-055070

Filed: 2026-05-12

Period: 2026-05-02

CIK: 0000025743

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Results of Operations and Financial Condition

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — ea0289776-8k_therapeu.htm (Primary)

EX-99.1 — PRESS RELEASE FROM THERAPEUTICSMD, INC., DATED MAY 12, 2026, ENTITLED "THERAPEUTICSMD ANNOUNCES FIRST QUARTER 2026 FINANCIAL RESULTS." (ea028977601ex99-1.htm)

GRAPHIC (ea028977601_ex99-1img1.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: ea0289776-8k_therapeu.htm · Sequence: 1

false

0000025743

2026-05-02

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED):

May 2, 2026

THERAPEUTICSMD, INC.

(Exact Name of Registrant as Specified in its

Charter)

Nevada

001-00100

87-0233535

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

951 Yamato Road, Suite 220

Boca Raton, FL 33431

(Address of Principal Executive Office) (Zip

Code)

Registrant’s telephone number, including

area code: (561) 961-1900

Not Applicable

(Former name or former address, if changed

since last report)

Check the appropriate box below if the Form 8-K filing is intended

to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class

Trading Symbol

Name of Each Exchange on Which Registered

Common Stock, par value $0.001 per share

TXMD

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth

company as defined in Rule 405 of the Securities Act of 1933 (§230-405) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant

has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant

to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial

Condition.

The information provided in Item 7.01 of this

Current Report on Form 8-K is incorporated in this Item 2.02 by reference.

Item 7.01 Regulation FD Disclosure.

On May 12, 2026, TherapeuticsMD, Inc., a

Nevada corporation (the “Company”), issued a press release announcing its financial results for the quarter ended March

31, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein

by reference.

The information in this Item 7.01 and the information

contained in Exhibit 99.1 is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange

Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933,

as amended, or the Exchange Act, except as may be expressly set forth by specific reference in any such filing, regardless of any general

incorporation language in the filing.

The Company does not have, and expressly disclaims,

any obligation to release publicly any updates or any changes in its expectations or any change in events, conditions, or circumstances

on which any forward-looking statement is based.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Index

Exhibit No.

Description

99.1

Press Release from TherapeuticsMD, Inc., dated May 12, 2026, entitled “TherapeuticsMD Announces First Quarter 2026 Financial Results.”

104

Cover Page Interactive Data File (the cover page tags are embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934,

the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 12, 2026

THERAPEUTICSMD, INC.

/s/ Marlan Walker

Marlan Walker

Chief Executive Officer

EX-99.1 — PRESS RELEASE FROM THERAPEUTICSMD, INC., DATED MAY 12, 2026, ENTITLED "THERAPEUTICSMD ANNOUNCES FIRST QUARTER 2026 FINANCIAL RESULTS."

EX-99.1

Filename: ea028977601ex99-1.htm · Sequence: 2

Exhibit 99.1

TherapeuticsMD Announces First Quarter 2026

Financial Results

BOCA RATON, Fla.--(BUSINESS WIRE)—May

12, 2026 -- TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights

to pharmaceutical royalties, today reported financial results for the three months ended March 31, 2026.

First Quarter 2026 Financial Results

Net Income (Loss) from Continuing Operations

● Net

income from continuing operations totaled $103 thousand, compared to a net loss of $636 thousand for the first quarter of 2025.

License Revenues from Continuing Operations

● The

Company recorded $724 thousand in license revenue, primarily from the Mayne License Agreement, an increase of $331 thousand, compared

to $393 thousand in license revenue for the first quarter of 2025. The increase is attributable to changes in sales of licensed products.

Total Operating Expenses from Continuing

Operations

● Total

operating expenses were $1,447 thousand, a decrease of $227 thousand, or 13.6%, compared to $1,674 thousand for the first quarter of

2025. The decrease is primarily attributable to the absence of write-off expense recognized in 2025, as well as lower professional fees

and share-based compensation costs.

Evaluation of Strategic Alternatives

● The Company continues to evaluate a variety of strategic alternatives that

may include, but are not limited to, an acquisition, merger, other business combination, sale of assets, or other strategic transactions

involving the Company. Although the Company is exploring potential strategic alternatives, there can be no assurance of a transaction,

a successful outcome of these efforts, or the form or timing of any such outcome. The Company has not established a timetable for completion

of this exploration process and does not intend to disclose further developments unless and until it is determined that disclosure is

appropriate or necessary.

Balance Sheet

● As of March 31, 2026, the Company’s cash and cash equivalents totaled

$8.4 million.

About TherapeuticsMD

TherapeuticsMD was previously a women’s

healthcare company with a mission of creating and commercializing innovative products to support the lifespan of women from pregnancy

prevention through menopause. In December 2022, the Company changed its business to become a pharmaceutical royalty company, primarily

collecting royalties from its licensees. The Company is no longer engaging in research and development or commercial operations.

Forward-Looking Statements

This press release by TherapeuticsMD, Inc.

may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to TherapeuticsMD’s

objectives, plans and strategies, including the exploration of potential strategic alternatives that may include, but are not limited

to, an acquisition, merger, other business combination, sale of assets, or other strategic transactions, and the completion of such a

review process and the potential timing, outcome and ability of any such strategic alternatives to create stockholder value, as well as

statements, other than historical facts, that address activities, events or developments that the Company intends, expects, projects,

believes or anticipates will or may occur in the future, including statements regarding the Company’s financial condition, liquidity,

results of operations and royalty revenues. These statements are often characterized by terminology such as “believes,” “hopes,”

“may,” “anticipates,” “should,” “intends,” “plans,” “will,” “expects,”

“estimates,” “projects,” “positioned,” “strategy” and similar expressions and are based

on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions,

expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as

of the date of this press release, and the Company undertakes no duty to update or revise any such statements, whether as a result of

new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks

and uncertainties, many of which are outside of the Company’s control. Important factors that could cause actual results, developments

and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors”

in the Company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly

Reports on Form 10-Q, as well as reports on Form 8-K, and include the following: whether the Company’s licensees will be successful

at commercializing the products that they licensed and acquired from TherapeuticsMD; the Company’s dependence upon third parties

for the manufacture and supply the Company’s women’s healthcare products; whether coverage and reimbursement is available

for the Company’s products; the outcome of the Company’s ongoing disputes with Mayne Pharma; time and costs associated with

winding down the Company’s operations; the Company’s ability to remain listed on Nasdaq; the impact of transitions in the

Company’s senior management team; the impact of government regulation, including those resulting from healthcare reform and drug

pricing initiatives; whether we are able to protect the proprietary nature of the intellectual property covering the Company’s hormone

therapy pharmaceutical products; competition from branded and generic products; and the Company’s ability to continue as a going

concern.

Marlan

D. Walker

Chief Executive Officer

561-961-1900

IR@TherapeuticsMD.com

Lisa

M. Wilson

In-Site Communications, Inc.

212-452-2793

lwilson@insitecony.com

Source: TherapeuticsMD, Inc.

GRAPHIC

Filename: ea028977601_ex99-1img1.jpg · Sequence: 3

Binary file (14824 bytes)

Download ea028977601_ex99-1img1.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

May 02, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

May 02, 2026

Entity File Number

001-00100

Entity Registrant Name

THERAPEUTICSMD, INC.

Entity Central Index Key

0000025743

Entity Tax Identification Number

87-0233535

Entity Incorporation, State or Country Code

Entity Address, Address Line One

951 Yamato Road

Entity Address, Address Line Two

Suite 220

Entity Address, City or Town

Boca Raton

Entity Address, State or Province

Entity Address, Postal Zip Code

33431

City Area Code

561

Local Phone Number

961-1900

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, par value $0.001 per share

Trading Symbol

TXMD

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration